VRTX Jan 2025 230.000 call
| Previous close | 140.78 |
| Open | 140.78 |
| Bid | 151.90 |
| Ask | 154.20 |
| Strike | 230.00 |
| Expiry date | 2025-01-17 |
| Day's range | 140.78 - 140.78 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
Associated Press FinanceVertex Pharma scientist talks about the long road to developing non-addictive painkillers
For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone. Opioid prescriptions have plummeted over the last decade as doctors have become more attuned to the risks of addiction and misuse during the country’s ongoing drug epidemic. Vertex Pharmaceuticals recently reported positive results for a non-opioid painkiller, one of several medications the Boston-based drugmaker has been developing for various forms of pain.
ZacksInvestors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ZacksAlpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
